For example, although we did not include it in our analysis, we identified one case of TMA following alemtuzumab administration in a patient with MS (in the absence of other potential causative agents) with an ADAMTS13 activity of 57 % [30]. The gene discussed is ADAMTS13; the disease is myeloid sarcoma.